XML 35 R4.htm IDEA: XBRL DOCUMENT v3.24.3
Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Revenues:        
Clinical treatment programs - US $ 35 $ 46 $ 125 $ 137
Total Revenues 35 46 125 137
Costs and Expenses:        
Production costs 8 30 24 30
Research and development 1,437 2,734 4,533 7,739
General and administrative 3,079 5,439 9,485 10,280
Total Costs and Expenses 4,524 8,203 14,042 18,049
Operating loss (4,489) (8,157) (13,917) (17,912)
Gain (loss) on investments 273 (310) 96 (201)
Interest and other income 718 294 3,379 811
Interest expense and other finance costs (202) (453)
Gain on sale of fixed assets 39 16
(Loss) on warrant issuance (458)
Gain from sale of income tax operating losses 318 900
Net Loss $ (3,700) $ (7,816) $ (11,353) $ (16,386)
Basic loss per share $ (0.06) $ (0.16) $ (0.21) $ (0.34)
Diluted loss per share $ (0.06) $ (0.16) $ (0.21) $ (0.34)
Weighted average shares outstanding basic 57,677,016 48,635,165 53,351,467 48,483,802
Weighted average shares outstanding diluted 57,677,016 48,635,165 53,351,467 48,483,802